申请人:Sumitomo Pharma Oncology, Inc.
公开号:US11529350B2
公开(公告)日:2022-12-20
Provided herein is a compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein values for the variables (e.g., X
1
, X
2
, R
2
, R
3
, R
4
, R
5
, R
6
, R
7
, R
8
, m, n) are as described herein. Compounds of Formula I, pharmaceutically acceptable salts thereof, pharmaceutical compositions of either of the foregoing, and combinations of any of the foregoing can be used to treat tyrosine kinase non-receptor 1 (TNK1)-mediated diseases, disorders and conditions.
本文提供了一种式 I.化合物或其药学上可接受的盐:
或其药学上可接受的盐,其中变量值(如 X
1
, X
2
, R
2
, R
3
, R
4
, R
5
, R
6
, R
7
, R
8
m,n)如本文所述。式 I 的化合物、其药学上可接受的盐、前述任一种的药物组合物以及前述任一种的组合物可用于治疗酪氨酸激酶非受体 1 (TNK1) 介导的疾病、失调和病症。